UNSPSC 51202806: Umirolimus

This classification denotes an immunosuppressant with the molecular formula C55H87NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) U36PGF65JH, chemically known as rapamycin, 42-o-(2-ethoxyethyl)- but more generally known as umirolimus, which bears US NIH Compound Identifier 11158972. European Medicines Agency schedules umirolimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33179.

UNSPSC 51202806 Umirolimus (Commodity) encompasses pharmaceutical and medical supply procurement by state and local health agencies, though recent solicitation activity under this code shows limited direct alignment with the umirolimus drug category itself. State and local governments buying under this code are acquiring generic pharmaceuticals, over-the-counter products, and emergency medical supplies through competitive bidding and cooperative purchasing frameworks. Issuing bodies include state health departments (Texas Health and Human Services Commission), county health agencies (Seminole County, Florida), municipal fire and rescue services (City of Tampa Fire Department), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The mix reflects both direct procurement by individual jurisdictions and aggregated purchasing through state-administered cooperative vehicles that serve multiple member agencies across multiple states.

Recent activity clusters in Florida, Texas, and Minnesota. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the City of Tampa's IFB 26P00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of medical and first aid supplies for the Fire Department Rescue Division, estimated at $700,000, with a sheltered-market 5 percent SLBE bid discount; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager channels; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed through authorized wholesalers across participating state and local facilities, with evaluation weighted 75 percent on price competitiveness and contract effectiveness July 1, 2026. Procurement patterns emphasize price competition, compliance with federal drug-supply-chain requirements, insurance and liability qualifications, and adherence to FDA and manufacturing standards.